• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

高效抗肥胖治疗时代的肥胖生活方式医学

Lifestyle Medicine for Obesity in the Era of Highly Effective Anti-Obesity Treatment.

作者信息

Sannidhi Deepa, Abeles Ruth, Andrew William, Bonnet Jonathan P, Vitale Kenneth, Niranjan Varalakshmi, Gulati Mahima, Pauly Kaitlyn, Moran Ryan, Alexander Lydia, Le Cassidy, Rajan Suraj, Romero Camila

机构信息

Department of Family Medicine, UC San Diego School of Medicine, La Jolla, CA 92093, USA.

Department of Internal Medicine, UC San Diego School of Medicine, La Jolla, CA 92093, USA.

出版信息

Nutrients. 2025 Jul 21;17(14):2382. doi: 10.3390/nu17142382.

DOI:10.3390/nu17142382
PMID:40733007
Abstract

Despite recent advances in the treatment of obesity, lifestyle medicine remains foundational to the treatment of individuals with obesity, regardless of the modality chosen by the patient with the guidance of the clinician they are working with, including in conjunction with, as appropriate, anti-obesity medications and metabolic surgery. Lifestyle medicine involves the use of diet, exercise, sleep, stress, and other lifestyle modalities in the treatment of disease. Clinicians and health systems should, after a patient-centered discussion with the patient, do their best to ensure access to lifestyle treatments. Gold standard guidelines recommend intensive, multicomponent lifestyle change programs for obesity treatments with evidence-based diet and exercise counseling and established, theoretically driven behavior change components. Clinicians treating obesity should be aware of their own biases, make efforts to reduce stigmatizing experiences in their practice, and address weight stigma in their treatment plans as needed. A variety of dietary patterns can be used to support patients with obesity, and clinicians should make evidence-based but patient-centered recommendations that aim to maximize adherence. Diet and exercise can play an important role in reducing the side effects of treatment and optimizing outcomes in weight loss, attenuating the effects of metabolic adaptation, and weight maintenance. Exercise should be increased gradually to reduce injury with a goal of 200-300 min (approximately 3.3-5 h) of moderate to vigorous intensity exercise per week to maximize weight maintenance effects with exercise prescriptions customized to patients risks. A variety of practice models can be leveraged along with the use of an interdisciplinary team to provide lifestyle medicine care for those with obesity.

摘要

尽管肥胖治疗最近取得了进展,但生活方式医学仍然是肥胖患者治疗的基础,无论患者在与其合作的临床医生的指导下选择何种治疗方式,包括在适当情况下结合抗肥胖药物和代谢手术。生活方式医学涉及使用饮食、运动、睡眠、压力和其他生活方式来治疗疾病。临床医生和医疗系统应在与患者进行以患者为中心的讨论后,尽力确保患者能够获得生活方式治疗。黄金标准指南推荐采用强化、多成分的生活方式改变计划来治疗肥胖,包括基于证据的饮食和运动咨询以及既定的、理论驱动的行为改变成分。治疗肥胖的临床医生应意识到自己的偏见,努力减少其医疗实践中的污名化现象,并在治疗计划中根据需要解决体重污名问题。可以采用多种饮食模式来支持肥胖患者,临床医生应做出基于证据但以患者为中心的建议,以最大限度地提高患者的依从性。饮食和运动在减轻治疗副作用、优化减肥效果、减弱代谢适应的影响以及维持体重方面可以发挥重要作用。运动应逐渐增加以减少受伤风险,目标是每周进行200 - 300分钟(约3.3 - 5小时)的中等至剧烈强度运动,根据患者风险定制运动处方,以最大限度地发挥维持体重的效果。可以利用多种实践模式,并借助跨学科团队为肥胖患者提供生活方式医学护理。

相似文献

1
Lifestyle Medicine for Obesity in the Era of Highly Effective Anti-Obesity Treatment.高效抗肥胖治疗时代的肥胖生活方式医学
Nutrients. 2025 Jul 21;17(14):2382. doi: 10.3390/nu17142382.
2
Prescription of Controlled Substances: Benefits and Risks管制药品的处方:益处与风险
3
Overcoming Stigma and Bias in Obesity Management克服肥胖管理中的耻辱感和偏见
4
Management of urinary stones by experts in stone disease (ESD 2025).结石病专家对尿路结石的管理(2025年结石病专家共识)
Arch Ital Urol Androl. 2025 Jun 30;97(2):14085. doi: 10.4081/aiua.2025.14085.
5
Clinical Practice Updates: AGA Clinical Practice Update on GI Manifestations and Autonomic or Immune Dysfunction in Hypermobile Ehlers-Danlos Syndrome: Expert Review.临床实践更新:美国胃肠病学会关于可弯曲性埃勒斯-当洛综合征的胃肠道表现及自主神经或免疫功能障碍的临床实践更新:专家综述
Clin Gastroenterol Hepatol. 2025 May 19. doi: 10.1016/j.cgh.2025.02.015.
6
[Guidelines for the prevention and management of bronchial asthma (2024 edition)].[支气管哮喘防治指南(2024年版)]
Zhonghua Jie He He Hu Xi Za Zhi. 2025 Mar 12;48(3):208-248. doi: 10.3760/cma.j.cn112147-20241013-00601.
7
Sexual Harassment and Prevention Training性骚扰与预防培训
8
What is the clinical effectiveness and cost-effectiveness of using drugs in treating obese patients in primary care? A systematic review.在初级保健中使用药物治疗肥胖患者的临床效果和成本效益如何?系统评价。
Health Technol Assess. 2012;16(5):iii-xiv, 1-195. doi: 10.3310/hta16050.
9
Patient Restraint and Seclusion患者约束与隔离
10
Interventions to improve safe and effective medicines use by consumers: an overview of systematic reviews.改善消费者安全有效用药的干预措施:系统评价概述
Cochrane Database Syst Rev. 2014 Apr 29;2014(4):CD007768. doi: 10.1002/14651858.CD007768.pub3.

本文引用的文献

1
The Impact of Physical Activity on Weight Loss in Relation to the Pillars of Lifestyle Medicine-A Narrative Review.体力活动对与生活方式医学支柱相关的体重减轻的影响——一项叙述性综述
Nutrients. 2025 Mar 20;17(6):1095. doi: 10.3390/nu17061095.
2
Expanding applications of GLP-1 therapies: a careful view.胰高血糖素样肽-1疗法的应用拓展:审慎看待
Int J Obes (Lond). 2025 Apr 16. doi: 10.1038/s41366-025-01788-4.
3
Preventing and Managing Pre- and Postoperative Micronutrient Deficiencies: A Vital Component of Long-Term Success in Bariatric Surgery.
预防和管理围手术期微量营养素缺乏:减重手术长期成功的关键要素
Nutrients. 2025 Feb 20;17(5):741. doi: 10.3390/nu17050741.
4
Trends in obesity and glucagon-like peptide-1 receptor agonist prescriptions in type 1 diabetes in the United States.美国1型糖尿病患者肥胖及胰高血糖素样肽-1受体激动剂处方的趋势
Diabetes Obes Metab. 2025 Jun;27(6):2967-2976. doi: 10.1111/dom.16300. Epub 2025 Mar 3.
5
Definition and diagnostic criteria of clinical obesity.临床肥胖的定义和诊断标准。
Lancet Diabetes Endocrinol. 2025 Mar;13(3):221-262. doi: 10.1016/S2213-8587(24)00316-4. Epub 2025 Jan 14.
6
Obesity and Severe Obesity Prevalence in Adults: United States, August 2021-August 2023.2021年8月至2023年8月美国成年人肥胖及重度肥胖患病率
NCHS Data Brief. 2024 Sep(508). doi: 10.15620/cdc/159281.
7
Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss Among Adults Without Diabetes : A Systematic Review of Randomized Controlled Trials.胰高血糖素样肽-1受体激动剂在无糖尿病成年人中减肥的疗效和安全性:随机对照试验的系统评价
Ann Intern Med. 2025 Feb;178(2):199-217. doi: 10.7326/ANNALS-24-01590. Epub 2025 Jan 7.
8
Dietary Recommendations for the Management of Gastrointestinal Symptoms in Patients Treated with GLP-1 Receptor Agonist.胰高血糖素样肽-1受体激动剂治疗患者胃肠道症状管理的饮食建议
Diabetes Metab Syndr Obes. 2024 Dec 19;17:4817-4824. doi: 10.2147/DMSO.S494919. eCollection 2024.
9
Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition: Systematic review and network meta-analysis.胰高血糖素样肽-1受体激动剂和协同激动剂对身体成分的影响:系统评价与网状荟萃分析。
Metabolism. 2025 Mar;164:156113. doi: 10.1016/j.metabol.2024.156113. Epub 2024 Dec 22.
10
GLP1Ra-based therapies and DXA-acquired musculoskeletal health outcomes: a focused meta-analysis of placebo-controlled trials.基于胰高血糖素样肽-1受体激动剂(GLP1Ra)的疗法与双能X线吸收法(DXA)获得的肌肉骨骼健康结果:安慰剂对照试验的聚焦荟萃分析
Obesity (Silver Spring). 2025 Feb;33(2):225-237. doi: 10.1002/oby.24172. Epub 2024 Dec 22.